Compare BridgeBio Pharma Inc (BBIO) vs Quanta Services Inc (PWR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Quanta Services Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Quanta Services Inc trades at $675 (market cap $99.36B). The key difference: Quanta Services Inc is far larger — about 6× BridgeBio Pharma Inc's market cap, and Quanta Services Inc pays a 0.07% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | PWR | |
|---|---|---|
Market Cap | $16.61B | $99.36B |
Sector | Health | Industrials |
52-Week High | $90.17 | $785.24 |
52-Week Low | $47.29 | $372.50 |
Enterprise Value | $18.16B | $105.45B |
Dividend Yield | — | 0.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
PWR trades at $671.86, up 0.6% in 24 hours, with a bullish technical signal and strong earnings beats in recent quarters. Revenue grew to $28.48B in 2025, and the company raised its 2026 outlook, supported by record backlog and infrastructure demand. Analysts show strong buy consensus with a $809.75 price target, though high valuation metrics like a P/E of 76.87 pose concerns.
The outlook is positive due to robust growth and institutional interest, but risks include elevated valuation and competitive pressures. Investment opportunity hinges on execution of raised guidance, while investors face volatility from market reactions to earnings and economic cycles.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Quanta Services Inc
Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under two reportable segments: electric power infrastructure solutions and underground utility and infrastructure solutions. In October 2021, the company completed the acquisition of Blattner, a provider of comprehensive engineering, procurement, and construction solutions to customers in the renewable energy industry.
Read more on PWR →
